Swiss biotech NLS Pharma's ADHD drug succeeds in mid-stage study

(Reuters) - Swiss biotech NLS Pharma AG said on Wednesday mid-stage trial data showed that its drug to treat attention deficit hyperactivity disorder (ADHD) greatly reduced symptoms in adults, paving the way for a late-stage trial.